(Date:5/9/2008)...., May 7 /PRNewswire-FirstCall/ -- Cynosure, Inc.,...urer of a broad array of,light-based aesthetic tre...ed market approval from the Korea Food & Drug Admi...rkstation for the removal of pigmented,lesions., ...ade is the third,Cynosure flagship product approve...
(Date:5/9/2008)... Calif., May 9 /PRNewswire-USNewsire/ -- U.S.,corp... to help victims of,the Cyclone Nargis in Myanmar ...elief International, to ensure that the aid will r...., "It,s important to remember the complete story...arts with the people and organizations that,provid...
(Date:5/9/2008)...ay 9 /PRNewswire/ -- Los Angeles based Operation U... assess the needs of what is now,an estimated 7 mi...destroyed or devastated wide swaths of Myanmar (ak...he capital Rangoon) and throughout its vast rice,g...120 miles per hour and,struck communities living l...
(Date:5/9/2008)... May 9 /PRNewswire/ -- OxyBand Technologies, Inc. ... the United States Army to,evaluate the company,s ...,battlefield and other military wounds. OxyBand Te...ing that delivers pure oxygen gas into wounds for,...n in clinical trials to,accelerate healing and, in...
Breaking Medicine News(10 mins):Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 2Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 3Health News:Direct Relief's Corporate Partners Key to Aiding Cyclone Victims 2Health News:Los Angeles Based Operation USA Appeals for Funds to Aid in Myanmar (Burmese) Cyclone Disaster (Updated) 2Health News:OxyBand Technologies Signs Army Contract 2...000 years ago, has been linked to many health bene...stroke and certain types of cancer. Researchers in...hat two compounds found in green tea, EGCG (epigal... can help prevent osteoarthritis by blocking the e...
...tion, which is very rare, affecting approximately ...bies are born without eyes i.e. they are born with...he foetus not developing eyes in the normal way in... this condition are often fitted with prosthetic e...
...t becomes so enlarged that it is no longer able to...in every 100,000 people. Researchers in the United... in the journal Science that a defect in the gene ... key role in regulating the flow of calcium throug...
...using a new imaging technique based on Magnetic Re...brain over time. Until now, MRI was used to show h...key area of the brain for memory and learning. And...astates even larger brain areas. This is the first...
Other Medicine News:(Date:5/9/2008)...irstCall/ -- Ardea Biosciences, Inc.,(Nasdaq: RDE...pment of,small- molecule therapeutics for the trea...cluding gout, today announced that John W. Beck,ha...d Operations and Chief,Financial Officer effective...rectors shortly thereafter. The Company also repor...
(Date:5/8/2008)...irstCall/ -- DATATRAK International, Inc.,(Nasdaq:...d on global,eClinical solutions for the clinical t...ts for the first quarter of 2008., For the three ...roximately 41% to $2,088,000 and the Company repor...re on both a basic and diluted basis. These,result...
(Date:5/8/2008)...otential of asenapine in the treatment of ...SHINGTON, May 8 /- Schering...that an overview of asenapine clinical trials,from...nual Meeting of the,American Psychiatric Associati...dies, involving patients with bipolar I disorder a...
(Date:5/8/2008)...swire-FirstCall/ -- VION PHARMACEUTICALS,INC. (Na...stigator-sponsored,Phase I/II clinical trial of it... in combination with cytarabine in elderly patient...emia (AML) and high-risk,myelodysplastic syndromes...ection of Ellen K. Ritchie, M.D. at The Weill-Corn...
Breaking Medicine Technology:Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3Protein shines light on cancer response 12538 1Protein shines light on cancer response 12538 2How to Be Heart Smart at the Supermarket 12535 1How to Be Heart Smart at the Supermarket 12535 2Ric Weiland Leaves 2465 Million to Support Gay Rights and HIV AIDS Organizations 12533 1Ric Weiland Leaves 2465 Million to Support Gay Rights and HIV AIDS Organizations 12533 2Ric Weiland Leaves 2465 Million to Support Gay Rights and HIV AIDS Organizations 12533 3Study Data Shows VNUS ClosureFAST 28TM 29 Catheter More than 96 25 Effective 1417 1Study Data Shows VNUS ClosureFAST 28TM 29 Catheter More than 96 25 Effective 1417 2Study Data Shows VNUS ClosureFAST 28TM 29 Catheter More than 96 25 Effective 1417 3Study Data Shows VNUS ClosureFAST 28TM 29 Catheter More than 96 25 Effective 1417 4... DIEGO, June 18, 2007 /PRNewswire-FirstCall/ -- Vi...s licensee, AnGes MG,Inc. reported positive resul...st 41 subjects to complete a Phase 3 trial of an,a...livery,technology. Based on the findings that the ...hieved with statistical,significance and that ther...
...LAN, Italy, June 15 /CNW/ - Today AMADEO, one of t...ial of two,angiotensin receptor blockers in hyper...esented at the European Society,of Hypertension, ...isartan reduces proteinuria to a significantly gre... on the results, Prof. Ellen Burgess, Foothills Ho...
Other Medicine Technology:Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 2Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 3Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 4Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 5New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 2New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 3New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 5Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm.
Straight tying forceps made of titanium has straight shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 105 mm.
Straight tying spring forceps made of titanium, delicate smooth jaws, length 10 mm, TCI jaws with round handle, diam. 8 mm and overall length 115 mm.
Tying forceps with flat serrated handle 88 mm, made of titanium, angled 30 with 4.5 mm tying platform.
Medicine Products: